PlainMeds provides educational information only. This is not medical advice. Always consult your doctor or pharmacist.
Active Shortage Injection Medical Imaging

Technetium TC-99M Pyrophosphate Kit Injection

Brand: TECHNESCAN PYP

This drug is currently listed as in shortage by the FDA. Affected manufacturer: Curium US LLC.

Active FDA Drug Shortage

Contact your pharmacist if you are affected. They can check availability from other manufacturers or suggest alternatives.

Shortage Details

Generic Name
Technetium TC-99M Pyrophosphate Kit Injection
Manufacturer
Curium US LLC
Dosage Form
Injection
Presentation
Technescan PYP, Injection, 11.9 mg/10 mL; 3.2 mg/10 mL (NDC 69945-094-20)
Package NDC
69945-094-20

Status & Timeline

Status
Active Shortage
Availability
Limited Availability
First Reported
Dec 27, 2023
Last Updated
Mar 18, 2026
Therapeutic Category
Medical Imaging

Shortage Reason

On allocation through Q2 2026

Nearby — Other Technetium Shortage Records

Frequently Asked Questions

Why is Technetium in shortage?
According to FDA data: On allocation through Q2 2026
What can I do if my medication is in shortage?
Contact your pharmacist — they can check availability across suppliers or suggest an equivalent from a different manufacturer. Your prescriber may also recommend a therapeutic substitute from the same drug class.
How often is this data updated?
Shortage data comes from the FDA Drug Shortages Database via openFDA. The database is updated regularly as manufacturers report changes to the FDA.

What This Technetium Shortage Record Means

The FDA Drug Shortages database lists this record for Technetium TC-99M Pyrophosphate Kit Injection (brand: TECHNESCAN PYP) from Curium US LLC with a current status of Active Shortage. The affected dosage form is Injection, presented as Technescan PYP, Injection, 11.9 mg/10 mL. Shortages are tracked at the manufacturer and presentation level — other manufacturers or formulations of the same generic may remain available, which is why pharmacists often can source a working substitute even when one record is flagged.

This shortage was first reported on Dec 27, 2023 and was last updated Mar 18, 2026. The FDA cites the following reason: On allocation through Q2 2026. There are 2 other current records in this database covering the same generic, which gives a fuller picture of how disruption is playing out across manufacturers and dosage forms.

A shortage listing is a supply-side signal, not a patient-level instruction. Access can vary dramatically by pharmacy, region, hospital system, and insurance formulary — local pharmacists have real-time visibility that a national database cannot provide. Therapeutic substitutes often exist in the same class, but switching decisions belong with your prescriber, who weighs efficacy, dosing conversion, interaction profile, and personal history. This page summarizes public FDA data for educational reference only and is not medical advice. If your medication is affected, contact your pharmacist and prescriber to plan an appropriate response.

Disclaimer: This information comes from the FDA Drug Shortages Database and is for educational purposes only. It is not medical advice. Do not stop or change any medication without consulting your healthcare provider or pharmacist. Shortage status can change rapidly — always verify current availability with your pharmacist.